Our Lab Receives RSRT Award to Advance RNA-Based Innovation for Rett Syndrome!
Apr 15
1 min read
0
67
0
We are delighted to announce that our lab has been selected by the Rett Syndrome Research Trust (RSRT) for a major award to further our efforts in developing cutting-edge RNA-based therapies. This recognition reflects not only the promise of our scientific direction but also the dedication of everyone in the lab pushing forward on tough problems.
Our project, which focuses on RNA trans-splicing to address mutations in MECP2, offers a strategy that could potentially apply to all Rett-causing mutations—not just one or a few. Rather than needing a specific fix for each different mutation, RNA trans-splicing could allow replacement of large sections of MECP2 RNA, offering broader therapeutic reach.
We are honored by RSRT’s support—both for its confidence in the feasibility of our approach and its alignment with RSRT’s mission to accelerate cures. This award will enable us to deepen our experiments, refine delivery methods, and move closer to translational readiness.
Thank you to our collaborators, lab members, and supporters who make work like this possible. With this new funding, we’re more motivated than ever to advance toward treatments that could make a real difference in the lives of Rett families.
